Download PDF
Thromb Haemost 1998; 79(02): 348-358
DOI: 10.1055/s-0037-1614990
Letters to the Editor
Schattauer GmbH

Phosphorothioate Oligodeoxyribonucleotides Antisense to PAI-1 mRNA Increase Fibrinolysis and Modify Experimental Thrombosis in Rats

Zofia Pawlowska
1   From the Department of Biophysics, Medical University of Lodz
,
Elzbieta Pluskota
1   From the Department of Biophysics, Medical University of Lodz
,
Ewa Chabielska
2   From the Department of Pharmacodynamics, Medical University of Bialystok
,
Wlodzimierz Buczko
2   From the Department of Pharmacodynamics, Medical University of Bialystok
,
Andrzej Okruszek
3   From the Department of Bioorganic Chemistry of the Center for Molecular and Macromolecular Studies
,
Wojciech J. Stec
3   From the Department of Bioorganic Chemistry of the Center for Molecular and Macromolecular Studies
,
Czeslaw S. Cierniewski
1   From the Department of Biophysics, Medical University of Lodz
4   From the Center of Microbiology and Virology, Polish Academy of Sciences, Lodz, Poland
› Author Affiliations
Further Information

Publication History

Received 09 April 1997

Accepted after resubmission 25 September 1997

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The effect of systemic inhibition of PAI-1 expression in rats by PS-16R, a phosphorothioate analogue of hexadecadeoxyribonucleotide complementary to a signal peptide coding sequence of rat PAI-1 mRNA, on PAI-1 activity in blood plasma and thrombus formation was studied in rat models for experimental thrombosis. In previous in vitro studies, oligonucleotides of PS-16R family have been shown to inhibit efficiently PAI-1 synthesis in endothelial cells by antisense mechanism. When PS-16R was administered intravenously as a single bolus injection (1 to 5 mg per rat), it produced a significant reduction in PAI-1 activity of blood plasma. This effect was both time- and concentration-dependent. Under the same conditions, three groups of rats were treated with control oligodeoxynucleotides such as PS-16R with double mismatches, with scrambled sequence, and an oligodeoxynucleotide with sense sequence (complementary to PS-16R), respectively. Based on these preliminary experiments, a low dose of 1.5 mg per rat was selected to produce approximately 20-30% reduction of PAI-1 activity in blood plasma and the effect of such a decrease in PAI-1 expression was tested on thrombus formation in two rat models for experimentally induced thrombosis. Such a limited decrease in PAI-1 activity produced a significant antithrombotic effect in the arterial thrombosis model. There was a profound delay in the occlusion time in rats treated with PS-16R when compared to control animals (80 ± 3 and 55 ± 3 h, respec tively), although blood plasma activity of PAI-1 in the same groups of rats differed only by 20%. There was also a tendency to reduce both an incidence of venous thrombosis (58.33 and 68.11%, respectively) and thrombus weight (2.1 ± 0.4 and 2.9 ± 0.9 mg, respectively) in the animals treated with PS-16R. However, this effect was not significant. Thus, low dose of PS-16R through inhibition of PAI-1 synthesis in targeted cells in rats reduced PAI-1 activity in blood plasma and protected against arterial thrombus formation in the rat.

 

  • References

  • 1 Krishnamurti C, Alving BM. Plasminogen activator inhibitor-1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 1992; 18: 67-80.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13.
    PubMedGoogle Scholar
  • 3 van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 261-76.
    PubMedGoogle Scholar
  • 4 Schneiderman J, Sawdey MS, Keeton MR. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
    CrossrefPubMedGoogle Scholar
  • 5 Hamsten A, De Faire U, Waldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
    PubMedGoogle Scholar
  • 6 Pralong G, Calandra T, Glauser MP. Plasminogen activator inhibitor: A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Ericson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusion in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
    CrossrefPubMedGoogle Scholar
  • 8 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-7.
    PubMedGoogle Scholar
  • 9 Knudson BS, Harpel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cell. J Clin Invest 1987; 80: 1082-9.
    CrossrefPubMedGoogle Scholar
  • 10 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
    PubMedGoogle Scholar
  • 11 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of radioimmunoassay and observations on its plasma concentration during venous occlusion and platelet aggregation. Blood 1987; 70: 1645-53.
    PubMedGoogle Scholar
  • 12 Vasalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
    CrossrefPubMedGoogle Scholar
  • 13 Levi M, Biemond BJ, van Zonneveld AJ, Wouter Ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
    CrossrefPubMedGoogle Scholar
  • 14 Charlton PA, Faint RW, Bent F, Bryant J, Mackie I, Machin S, Bevan P. A series of low molecular weight inhibitors of plasminogen activator inhibitor-1 increase fibrinolysis and protect against thrombus formation in the rat. Thromb Haemost 1995; 73: 1005-9.
    PubMedGoogle Scholar
  • 15 Eitzman DT, Fay PW, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-20.
    CrossrefPubMedGoogle Scholar
  • 16 Cierniewski CS, Babinska A, Swiatkowska M, Wilczynska M, Okruszek A, Stec WJ. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells. Eur J Biochem 1995; 227: 494-9.
    CrossrefPubMedGoogle Scholar
  • 17 Sawa H, Sobel BE, Fuji S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem 1994; 269: 14149-52.
    PubMedGoogle Scholar
  • 18 Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 1995; 91: 1175-81.
    CrossrefPubMedGoogle Scholar
  • 19 Koziolkiewicz M, Wojcik M, Kobylanska A, Karwowski B, Rebowski B, Guga P, Stec WJ. Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma. Antisense Nucl Acid Drug Dev 1997; 7: 43-8.
    CrossrefPubMedGoogle Scholar
  • 20 Zon G, Stec WJ. Phosphorothioate oligonucleotides. In: Oligonucleotides and Analogues. Eckstein F. (ed). IRL PRESS; New York: 1991. pp 87-108.
    Google Scholar
  • 21 Stec WJ, Uznañski B, Wilk A, Hirschbein BL, Fearon KL, Bergot BJ. Bis(O,O-Diisopropoxy Phosphinothioyl) Disulfide – A highly efficient sulfurizing reagent for cost-effective synthesis of oligo(nucleoside phosphothioate)s. Tetrahedron Lett 1993; 34: 5317-20.
    CrossrefPubMedGoogle Scholar
  • 22 Lewis ML, Nachtwey DS, Damron KL. A miniaturized fibrinolytic assay for plasminogen activators. Thrombosis Research 1991; 64: 223-34.
    CrossrefPubMedGoogle Scholar
  • 23 Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-74.
    CrossrefPubMedGoogle Scholar
  • 24 Hornstra G, Vendelmans-Starrenburg A. Induction of experimental occlusive thrombi in rats. Atherosclerosis 1973; 17: 369-82.
    CrossrefPubMedGoogle Scholar
  • 25 Dejana E, Villa S, De Gaetano G. Bleeding time in rats: A comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim 1991; 25: 26-9.
    CrossrefPubMedGoogle Scholar
  • 27 Vaughan DE, Declerck PJ, De MoL M, Collen D. Recombinant plasminogen activator inhibitor-1 reverse the bleeding tendency associated with the combined administration of tissue-type plasminogen activator. J Clin Invest 1989; 84: 586-91.
    CrossrefPubMedGoogle Scholar
  • 28 Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPA-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Eriksson BI, Eriksson E, Gyzander E, Teger-Nilsson AC, Risberg B. Thrombosis after replacement. Relationship of the fibrinolytic system. Acta Orthop Scand 1989; 60: 159-63.
    CrossrefPubMedGoogle Scholar
  • 30 Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thrombo-embolism in orthopedic patients. Thromb Res 1991; 1-2: 55-64.
    PubMedGoogle Scholar
  • 31 Masuda T, Yasue H, Ogawa H, Misumi I, Sakamoto T, Okubo H, Miyao Y, Kato H. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J 1992; 124: 314-9.
    CrossrefPubMedGoogle Scholar
  • 32 Ihnken K, Speiser W, Ruf W, Thiel W, Schlepper M, Müller-Berghaus G. High PAI activity with correlation to trigliceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction. Ann Hematol 1993; 67: 237-44.
    CrossrefPubMedGoogle Scholar
  • 33 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherosclerosis. Thromb Haemost 1993; 70: 138-43.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Paramo JA, Colluci M, Collen D, van der Werf F. Plasminogen activator inhibitor in the blood patients with coronary artery disease. Br Med J 1985; 291: 575-84.
    CrossrefPubMedGoogle Scholar
  • 35 Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-51.
    CrossrefPubMedGoogle Scholar
  • 36 Wyroba E, Pawlowska Z, Kobylanska A, Pluskota E, Maszewska M, Stec WJ, Cierniewski CS. Internalization of oligodeoxynucleotide antisense to type-1 plasminogen activator inhibitor mRNA in endothelial cells: A three-dimensional reconstruction by confocal microscopy. Biol. Cell 1996; 87: 37-43.
    PubMedGoogle Scholar
  • 37 Cierniewski CS, Pawlowska Z, Pluskota E, Stasiak M, Kobylanska A, Koziolkiewicz M, Maciaszek A, Misiura K, Stec WJ, Wyroba E. In vitro and in vivo studies on oligonucleotides PS16 which is antisense to PAI-1 mRNA. Fibrynolysis 1996; 10 (Suppl. 03) 416.
    PubMedGoogle Scholar
  • 38 Cierniewski CS, Pluskota E, Krzeslowska J, Fijalkowska I, Kobylanska A, Koziolkiewicz M, Okruszek A, Stec WJ. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells. Thromb Haemost 1995; 73: 411.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Hirsh J, Brain EA. Pathogenesis of thrombosis. In: Hemostasis & Thrombosis. A conceptual approach. Churchill Livingstone Inc; New York: 1983. pp. 92-109.
    Google Scholar
  • 40 Iacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 1996; 76: 1102-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Reyers I, Hennissen A, Donati MB, Hornstra G, de Gaetano G. Aspirin and the prevention of experimental arterial thrombosis; difficulty in establishing unequivocal effectiveness. Thromb Haemost 1985; 54: 619-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Mysliwiec M, Villa S, Korriburitt L, de Gaetano G, Donati MB. Decreased plasminogen activator but normal prostacyclin activity in rat veins during development of experimental thrombosis. Thromb Res 1980; 18: 159-65.
    CrossrefPubMedGoogle Scholar
  • 43 Chabielska E, Kolpakov V, D’Adamo MC, De Curtis A, Buczko W, Iacoviello L, Donati MB. Morphological and hemostatic changes in rats with abdominal prosthesis. Thromb Res 1996; 82: 69-77.
    CrossrefPubMedGoogle Scholar
  • 44 Booth NA, Simoson AJ, Croll A, Bennet B, MacGregor IR. PAI-1 in plasma and platelets. Br J Haematol 1988; 70: 327-33.
    CrossrefPubMedGoogle Scholar
  • 45 Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW. A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization. Blood 1997; 89: 823-33.
    PubMedGoogle Scholar